Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAEED SADEGHI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1144240334
CMS profile
6794
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$147,292.56

166 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAEED SADEGHI

NPI 1144240334 · CMS profile ID 6794

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144240334?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAEED SADEGHI, NPI 1144240334, CMS profile ID 6794. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144240334?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SAEED SADEGHI, NPI 1144240334, CMS profile ID 6794. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144240334?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SAEED SADEGHI, NPI 1144240334, CMS profile ID 6794, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–166 of 166 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1144240334?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

166 matching records · $147,292.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 166 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–166 of 166.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $337.2102/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294355 CMS
Pharmacyclics LLC, An AbbVie Company $363.5202/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294357 CMS
Pharmacyclics LLC, An AbbVie Company $56.7402/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294351 CMS
Pharmacyclics LLC, An AbbVie Company $667.8602/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294353 CMS
BeiGene USA, Inc. $17.3102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051192437 CMS
Pharmacyclics LLC, An AbbVie Company $125.0002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294347 CMS
Pharmacyclics LLC, An AbbVie Company $694.9602/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294349 CMS
Pharmacyclics LLC, An AbbVie Company $124.9801/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294345 CMS
Eisai Inc. $1,020.0001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023330787 CMS
Lilly USA, LLC $24.0201/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032336263 CMS
Mirati Therapeutics, Inc. $136.4301/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058002065 CMS
Janssen Biotech, Inc. $113.0301/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988048461 CMS
Janssen Biotech, Inc. $184.3701/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988048451 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0001/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294343 CMS
GlaxoSmithKline, LLC. $1,200.0001/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003002889 CMS
Janssen Biotech, Inc. $1,500.0001/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988048439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $177,645.37 211
PY2020 $49,489.68 90
PY2021 $32,877.42 51
PY2022 $142,089.28 154
PY2023 $147,292.56 166
PY2024 $48,500.67 92
PY2025 $98,173.93 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $538,139.72 65
PY2024 Recipient $2,724.17 4
PY2024 Principal investigator $471,710.32 31
PY2023 Principal investigator $70,456.35 9
PY2022 Principal investigator $109,512.99 3
PY2021 Principal investigator $112,852.76 10
PY2020 Principal investigator $54,627.46 5
PY2019 Principal investigator $103,089.64 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $3,603.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554827
Principal investigator 1 Genentech, Inc. $5,446.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554831
Principal investigator 1 Genentech, Inc. $732.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554835
Principal investigator 1 Genentech, Inc. $4,096.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554840
Principal investigator 1 Genentech, Inc. $267.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554843
Principal investigator 1 Genentech, Inc. $5,924.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554851
Principal investigator 1 Genentech, Inc. $280.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554854
Principal investigator 1 Genentech, Inc. $150.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554859
Principal investigator 1 Genentech, Inc. $293.00 12/19/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554862
Principal investigator 1 Genentech, Inc. $6,760.00 12/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554823
Principal investigator 1 Genentech, Inc. $3,990.00 12/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554847
Principal investigator 1 PFIZER INC. $1,890.00 12/13/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228816991
Principal investigator 1 PFIZER INC. $52,475.65 12/12/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228815028
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,201.35 12/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735882
Principal investigator 1 PFIZER INC. $728.00 11/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228813482
Principal investigator 1 Genentech, Inc. $80.00 10/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554814
Principal investigator 1 Genentech, Inc. $26,360.00 10/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554818
Principal investigator 1 Genentech, Inc. $16,516.00 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554495
Principal investigator 1 PFIZER INC. $26,034.00 10/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228819337
Principal investigator 1 Novartis Pharmaceuticals Corporation $912.43 10/08/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors No dispute reported 06/30/2026 1190302543
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $794.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735870
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $756.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735872
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,591.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735874
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,890.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735876
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,890.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735878
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,520.00 09/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735880
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,591.00 08/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735866
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,890.00 08/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735868
Principal investigator 1 PFIZER INC. $7,854.00 08/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228843379
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,546.52 07/30/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors No dispute reported 06/30/2026 1190302545
Principal investigator 1 Genentech, Inc. $740.00 07/29/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554484
Principal investigator 1 PFIZER INC. $1,859.76 07/24/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228846961
Principal investigator 1 Genentech, Inc. $3,876.00 07/10/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554491
Principal investigator 1 Genentech, Inc. $33,592.00 07/07/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554487
Principal investigator 1 PFIZER INC. $7,555.30 06/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228851876
Principal investigator 1 Genentech, Inc. $5,118.12 06/13/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554759
Principal investigator 1 Genentech, Inc. $45,671.00 06/13/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554764
Principal investigator 1 Genentech, Inc. $8,260.00 05/21/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554476
Principal investigator 1 PFIZER INC. $3,573.70 05/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858442
Principal investigator 1 Blueprint Medicines Corporation $1,890.00 05/08/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784858
Principal investigator 1 Blueprint Medicines Corporation $756.00 05/08/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1235784863
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,186.00 05/06/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735862
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,562.00 05/06/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735864
Principal investigator 1 PFIZER INC. $3,573.70 05/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858466
Principal investigator 1 Genentech, Inc. $7,135.00 05/02/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554750
Principal investigator 1 Genentech, Inc. $2,993.00 05/02/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211554754
Principal investigator 1 Genentech, Inc. $15,254.00 04/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211554479
Principal investigator 1 PFIZER INC. $1,622.51 04/08/2025 Non-covered Recipient Entity
Ronald Reagan UCLA Med Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840934
Principal investigator 1 PFIZER INC. $1,622.51 03/10/2025 Non-covered Recipient Entity
Ronald Reagan UCLA Med Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228840568
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22,956.75 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,353.70 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735852
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,593.10 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735854
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,341.90 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735856
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32,071.05 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735858
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $29,092.80 03/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735860
Principal investigator 1 Genentech, Inc. $5,040.00 02/20/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211553434
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,353.70 02/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735844
Principal investigator 1 PFIZER INC. $3,245.02 02/19/2025 Non-covered Recipient Entity
Ronald Reagan UCLA Med Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228841273
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $19,559.55 02/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,547.05 02/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735846
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $25,286.15 02/18/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735848
Principal investigator 1 PFIZER INC. $3,573.70 02/13/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228839752
Principal investigator 1 PFIZER INC. $325.00 02/10/2025 Non-covered Recipient Entity
Ronald Reagan UCLA Med Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228841278
Principal investigator 1 PFIZER INC. $325.00 01/07/2025 Non-covered Recipient Entity
Ronald Reagan UCLA Med Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228841232
Principal investigator 1 PFIZER INC. $3,573.70 01/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863911